NATIONAL TAIWAN UNIVERSITY HOSPITAL
- Country
- 🇹🇼Taiwan
- Ownership
- Private
- Established
- 1895-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.ntuh.gov.tw
Clinical Trials
2.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1238 trials with phase data)• Click on a phase to view related trials
Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based Therapy
- Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07072637
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics
- Conditions
- Age-Related Macular Degeneration (AMD)Diabetic Retinopathy (DR)
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 4300
- Registration Number
- NCT07069647
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Safety and Clinical Efficacy of Histotripsy for Liver Cancers Adjacent to Major Intrahepatic Vessels
- Conditions
- Liver Tumors
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07063771
Exploring the Application of Virtual Reality in Enhancing Chest Percussion Techniques, Reducing Caregiver Stress, and Improving Teaching Effectiveness for Caregivers of Children With Pneumonia
- Conditions
- Virtual Reality
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT07048275
- Locations
- 🇨🇳
Hui-Mei, Chen, Yuanlin, Taiwan
Primary Resistance Mechanisms of ALK TKIs
- Conditions
- ALK-positive Advanced NSCLC PatientsPrimary ResistanceNGS
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07045610
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- 3
- 4
- 5
- 483
- Next
News
3D Pathology Technology Reclassifies 67% of HER2-Null Breast Cancer Cases as HER2-Expressing
• JelloX Biotech's 3D pathology technology identified significantly more HER2-low and HER2-ultralow breast tumors compared to conventional diagnostic methods in a study with National Taiwan University Hospital. • Over 50% of analyzed breast cancer cases showed diagnostic discrepancies when re-evaluated with 3D pathology, with 66.7% of initially HER2-null patients reclassified as HER2-expressing. • The improved detection sensitivity could expand treatment eligibility for Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that has shown robust efficacy in HER2-low and HER2-ultralow metastatic breast cancer.
Ainos Advances VELDONA Oral Interferon Platform with Dual Clinical Trial Approvals for Rare Diseases
Ainos has secured TFDA approval for a clinical trial of VELDONA in HIV-related oral warts and IRB clearance for a Sjögren's Syndrome study, targeting two rare diseases with significant unmet needs.
Volition's Nu.Q® Cancer Test Shows Promise in Lung Cancer Screening and Pan-Cancer Detection
Volition has enrolled the first patient in a 500-patient validation study at National Taiwan University Hospital to evaluate Nu.Q® Cancer technology for distinguishing between malignant and benign pulmonary nodules in LDCT lung cancer screening.
Novel Small-Molecule Drug Shows Promise in Treating Inflammatory Bowel Disease
Taiwanese researchers from NTHU and NHRI have developed a breakthrough small-molecule drug that treats chronic intestinal inflammation by blocking PANX1 ion channels in intestinal cells.